Supernus Pharmaceuticals, Inc. Stock News

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care ...

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript

ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for fourth quarter and full year 2024 and associated Company developments.

BOSTON, MA / ACCESS Newswire / February 24, 2025 / Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) for potential securities law violations. Investors who have lost money in their Supernus Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses.

BOSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential securities law violations. Investors who have lost money in their Supernus Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses.

ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD) did not demonstrate a statistically significant improvemen...

ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday...